CN102805882A - 一种软组织填充剂在使用前与麻醉剂注射液混合的方法 - Google Patents
一种软组织填充剂在使用前与麻醉剂注射液混合的方法 Download PDFInfo
- Publication number
- CN102805882A CN102805882A CN2012103096844A CN201210309684A CN102805882A CN 102805882 A CN102805882 A CN 102805882A CN 2012103096844 A CN2012103096844 A CN 2012103096844A CN 201210309684 A CN201210309684 A CN 201210309684A CN 102805882 A CN102805882 A CN 102805882A
- Authority
- CN
- China
- Prior art keywords
- syringe
- fix liquid
- soft tissue
- volume
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000945 filler Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 51
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 42
- 238000002156 mixing Methods 0.000 title claims abstract description 15
- 230000003444 anaesthetic effect Effects 0.000 title description 3
- 238000002347 injection Methods 0.000 claims abstract description 57
- 239000007924 injection Substances 0.000 claims abstract description 57
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 94
- 229940090044 injection Drugs 0.000 claims description 53
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 11
- 229960004194 lidocaine Drugs 0.000 claims description 11
- 229940071643 prefilled syringe Drugs 0.000 claims description 11
- -1 ovocaine Chemical compound 0.000 claims description 8
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 4
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960003150 bupivacaine Drugs 0.000 claims description 4
- 229960003976 etidocaine Drugs 0.000 claims description 4
- SIEYLFHKZGLBNX-NTISSMGPSA-N levobupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-NTISSMGPSA-N 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 229940025300 lidocaine injection Drugs 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 2
- 230000036407 pain Effects 0.000 abstract description 20
- 229940035674 anesthetics Drugs 0.000 abstract description 6
- 239000003193 general anesthetic agent Substances 0.000 abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 229920002674 hyaluronan Polymers 0.000 abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 17
- 230000003796 beauty Effects 0.000 description 9
- 230000003533 narcotic effect Effects 0.000 description 9
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 6
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001269238 Data Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210309684.4A CN102805882B (zh) | 2012-08-28 | 2012-08-28 | 一种软组织填充剂在使用前与麻醉剂注射液混合的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210309684.4A CN102805882B (zh) | 2012-08-28 | 2012-08-28 | 一种软组织填充剂在使用前与麻醉剂注射液混合的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102805882A true CN102805882A (zh) | 2012-12-05 |
CN102805882B CN102805882B (zh) | 2014-04-23 |
Family
ID=47229864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210309684.4A Active CN102805882B (zh) | 2012-08-28 | 2012-08-28 | 一种软组织填充剂在使用前与麻醉剂注射液混合的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102805882B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3015290A1 (fr) * | 2013-12-23 | 2015-06-26 | Vivacy Lab | Compositions d'acide hyaluronique compreant de la mepivacaine |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
CN111787966A (zh) * | 2017-12-19 | 2020-10-16 | 大化制药株式会社 | 包含局部麻醉药和透明质酸水凝胶的预填充式注射器的制造方法 |
CN113546539A (zh) * | 2020-04-24 | 2021-10-26 | 透策生技股份有限公司 | 利用加压手段以加速注射式填充物分散的处理方法 |
CN113648459A (zh) * | 2013-07-30 | 2021-11-16 | 泰奥赛恩公司 | 包含透明质酸和甲哌卡因的组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4243080A (en) * | 1977-10-06 | 1981-01-06 | American Hospital Supply Corporation | Method of mixing plural components |
US4254768A (en) * | 1979-09-14 | 1981-03-10 | Ty Perla J | Hypodermic syringe |
US4743229A (en) * | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
CN101027065A (zh) * | 2004-06-15 | 2007-08-29 | 陈献 | 磷脂组合物及其制备和使用方法 |
-
2012
- 2012-08-28 CN CN201210309684.4A patent/CN102805882B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4243080A (en) * | 1977-10-06 | 1981-01-06 | American Hospital Supply Corporation | Method of mixing plural components |
US4254768A (en) * | 1979-09-14 | 1981-03-10 | Ty Perla J | Hypodermic syringe |
US4743229A (en) * | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
CN101027065A (zh) * | 2004-06-15 | 2007-08-29 | 陈献 | 磷脂组合物及其制备和使用方法 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113648459A (zh) * | 2013-07-30 | 2021-11-16 | 泰奥赛恩公司 | 包含透明质酸和甲哌卡因的组合物 |
FR3015290A1 (fr) * | 2013-12-23 | 2015-06-26 | Vivacy Lab | Compositions d'acide hyaluronique compreant de la mepivacaine |
WO2015097261A1 (fr) * | 2013-12-23 | 2015-07-02 | Laboratoires Vivacy | Compositions d'acide hyaluronique comprenant de la mepivacaïne |
JP2017500358A (ja) * | 2013-12-23 | 2017-01-05 | ラボラトアール ヴィヴァシィ | メピバカインを含有するヒアルロン酸組成物 |
EP3173086A1 (fr) | 2013-12-23 | 2017-05-31 | Laboratoires Vivacy | Compositions d'acide hyaluronique comprenant de la mépivacaïne |
FR3044228A1 (fr) * | 2013-12-23 | 2017-06-02 | Lab Vivacy | Compositions d'acide hyaluronique comprenant de la mepivacaine |
EA031349B1 (ru) * | 2013-12-23 | 2018-12-28 | Лаборатуар Виваси | Композиция гиалуроновой кислоты, включающая мепивакаин |
EA036502B1 (ru) * | 2013-12-23 | 2020-11-17 | Лаборатуар Виваси | Композиции гиалуроновой кислоты, включающие мепивакаин |
EP3799875A1 (fr) * | 2013-12-23 | 2021-04-07 | Laboratoires Vivacy | Compositions d'acide hyaluronique comprenant de la mépivacaïne |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
CN111787966A (zh) * | 2017-12-19 | 2020-10-16 | 大化制药株式会社 | 包含局部麻醉药和透明质酸水凝胶的预填充式注射器的制造方法 |
CN113546539A (zh) * | 2020-04-24 | 2021-10-26 | 透策生技股份有限公司 | 利用加压手段以加速注射式填充物分散的处理方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102805882B (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102805882B (zh) | 一种软组织填充剂在使用前与麻醉剂注射液混合的方法 | |
US8142817B2 (en) | Composition for restoration of age related tissue loss in the face or selected areas of the body | |
Romagnoli et al. | Hyaluronic acid–based fillers: theory and practice | |
BR112015031026B1 (pt) | método para reticulação de ácido hialurônico ou um dos seus sais ou outros polímeros biocompatíveis; método para preparação de um hidrogel injetável; hidrogel; kit e uso | |
CN102724951A (zh) | 用于刺激毛发生长的组合物和方法 | |
CN105748315B (zh) | 一种修复皮肤屏障的组合物 | |
Daumas et al. | Fat grafting for treatment of facial scleroderma | |
Kapoor et al. | Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks? | |
AU2014217942B2 (en) | Compositions and methods for pain relief without numbness | |
WO1993002699A1 (de) | Verwendung von kollagen zur behandlung von degenerativen gelenkprozessen | |
Vedamurthy | Soft tissue augmentation-Use of hyaluronic acid as dermal filler | |
CN106176758B (zh) | 一种外用药物组合物 | |
US20210145955A1 (en) | Clostridial neurotoxin formulations and use | |
CN110151687A (zh) | 一种稳定的水合氯醛溶液及其制备方法和用途 | |
ATE298256T1 (de) | Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung | |
Al-Khafaji et al. | The Application and Efficacy of Hyaluronic Acid Fillers for Chin Enhancement and Retrusion Correction: A Systematic Review of Patient-Reported Outcomes | |
Van Loghem | Use of calcium hydroxylapatite for augmentation of the labia majora and mons pubis | |
CN107252490B (zh) | 一种局麻药物及其制备方法 | |
CN100443078C (zh) | 一种皮肤表面局部麻醉镇痛凝胶剂及用途 | |
Coimbra et al. | Injectable Poly-L-Lactic Acid for the Arms | |
CN117618445B (zh) | 一种用于龟鳖目动物的复方麻醉剂及制备方法和应用 | |
KR20090011604U (ko) | 무통 관절강내주사 | |
YUTSKOVSKAYA et al. | Neck and chest | |
CN105878427A (zh) | 一种治疗烧烫伤的牡丹籽油复方喷雾剂及制备方法 | |
Yutskovskaya et al. | Neck and chest: MesoCaHA for cheeks, neck, and décolletage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING BLOOMAGE HYINC TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BLOOMAGE FREDA BIOPHARM CO., LTD. Effective date: 20140605 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 100022 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140605 Address after: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee after: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. Address before: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee before: BLOOMAGE FREDA BIOPHARM Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: 250101 high tech Zone, Shandong, Ji'nan Century Avenue, No. 3333 Patentee after: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. Address before: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee before: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230620 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee after: BLOOMAGE BIOTECH Co.,Ltd. Address before: 250101 No. 3333, Century Avenue, high tech Zone, Ji'nan, Shandong Patentee before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |
|
TR01 | Transfer of patent right |